



Biomarkers Consortium Membership

The Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH) is the preeminent public-private partnership focused on developing biomarkers that accelerate therapeutics and improve clinical care. Join the National Institutes of Health (NIH), Food & Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA) and over 50 companies and not-for-profit organizations in supporting the efforts of the Consortium. Large or small, public or private, established or growing, as a member your organization will benefit from active participation in the Consortium's engaging and impactful work.

Core activities of the Biomarkers Consortium are funded by membership dues from the private sector. Corporations, firms, advocacy groups, not-for-profit organizations, associations and philanthropic organizations interested in supporting biomarker development are eligible to become contributing members. Members elect representatives to serve on multi-stakeholder Steering Committees driving the work of the Consortium. Current Steering Committees are focused on developing projects in Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience.

MEMBERSHIP PROVIDES THE OPPORTUNITY TO:

- Partner to create and lead cross-sector efforts to validate and qualify biomarkers and other drug development tools
- Collaborate with leaders and colleagues from industry, academia, NIH, FDA, patient/advocacy organizations and other sectors
- Leverage expertise, data and resources in unique pre-competitive research programs
- Engage in the design, execution, and implementation of individual projects as part of specific Project Teams
- Accelerate the development of new therapeutics and health technologies
- Contribute directly to science that supports regulatory decision-making
- Consider first-tier opportunities to participate in projects as funding partners
- Gain pre-competitive scientific insights that could inform business strategies
- Participate in Consortium communications and publicity activities
- Receive frequent updates and stay informed on the status of the Consortium's activities, emerging trends and new opportunities for involvement

Enterprise Membership allows companies and not-for-profit organizations to participate in all Consortium Steering Committees (Cancer, Inflammation and Immunity, Metabolic Disorders, and Neuroscience). In addition, Enterprise Members are eligible for election to the Executive Committee that oversees and approves the Consortium's work.

Per-Committee Membership is available to for-profit companies interested in joining select Steering Committees and with an annual research and development budget of at least \$100 million. These members may nominate representatives for co-chair positions on chosen Steering Committee(s). Membership in at least two committees is required to be eligible for election to the Executive Committee that oversees and approves the Consortium's work.

MEMBERSHIP DUES

Membership is offered at several levels based on organization type and research and development budgets, if applicable within your industry. Membership extends 12 months from the date a signed membership agreement is received by the FNIH. Enterprise Members who elect to make a three-year commitment in one payment will receive a 10% membership discount.

ENTERPRISE MEMBERSHIP

SIZE OF R&D BUDGET	ANNUAL MEMBERSHIP	MEMBERSHIP FOR THREE YEARS
\$3 billion+	\$150,000	\$405,000
\$1-3 billion	\$100,000	\$270,000
\$100 million - \$1 billion	\$50,000	\$135,000
Under \$100 million	\$10,000	\$27,000
Not-for-profit organization	\$5,000	\$13,500

PER-COMMITTEE MEMBERSHIP

SIZE OF R&D BUDGET	ANNUAL PRICE PER COMMITTEE
\$3 billion+	\$40,000
\$1-3 billion	\$28,000
\$100 million - \$1 billion	\$15,000

CURRENT MEMBERS OF THE BIOMARKERS CONSORTIUM:



To learn more about how you can become a member of the Biomarkers Consortium, please contact:

 **Heidi Blythe**
 Director of Development
 (301) 443-1744
 hblythe@fnih.org

The Foundation for the National Institutes of Health (FNIH) is a not-for-profit organization chartered by Congress to create and lead alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people's lives. To learn more, visit: <https://fnih.org/>. One such partnership, led by the FNIH, is the Biomarkers Consortium, which is helping to create a new era of precision medicine by accelerating the development of biomarker-based technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease. To learn more, visit: <https://fnih.org/what-we-do/biomarkers-consortium>.